Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Marc Dror Michaelson, Ph.D., M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Lee CH, Motzer RJ, Glen H, Michaelson MD, Larkin J, Minoshima Y, Kanekiyo M, Ikezawa H, Sachdev P, Dutcus CE, Funahashi Y, Voss MH. Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. Br J Cancer. 2020 Oct 07. PMID: 33024271.
    Citations:    Fields:    
  2. Nuzzo PV, Berchuck JE, Korthauer K, Spisak S, Nassar AH, Alaiwi SA, Chakravarthy A, Shen SY, Bakouny Z, Boccardo F, Steinharter J, Bouchard G, Curran CR, Pan W, Baca SC, Seo JH, Lee GM, Michaelson MD, Chang SL, Waikar SS, Sonpavde G, Irizarry RA, Pomerantz M, De Carvalho DD, Choueiri TK, Freedman ML. Author Correction: Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat Med. 2020 Oct; 26(10):1663. PMID: 32895574.
    Citations:    Fields:    
  3. Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, Alva A, Beckermann K, Choueiri TK, Costello BA, Derweesh IH, Desai A, George S, Gore JL, Haas N, Hancock SL, Kyriakopoulos C, Lam ET, Lau C, Lewis B, Madoff DC, McCreery B, Michaelson MD, Mortazavi A, Nandagopal L, Pierorazio PM, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Somer B, Sosman J, Dwyer MA, Motter AD. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. J Natl Compr Canc Netw. 2020 09; 18(9):1160-1170. PMID: 32886895.
    Citations:    Fields:    
  4. Reynolds KL, Klempner SJ, Parikh A, Hochberg EP, Michaelson MD, Mooradian MJ, Lee RJ, Soumerai TE, Hobbs G, Piotrowska Z, Sykes DB, Farago AF, Bardia A, Rosovsky RP, Ryan DP. The Art of Oncology: COVID-19 Era. Oncologist. 2020 Jul 22. PMID: 32697887.
    Citations:    Fields:    
  5. Nuzzo PV, Berchuck JE, Korthauer K, Spisak S, Nassar AH, Abou Alaiwi S, Chakravarthy A, Shen SY, Bakouny Z, Boccardo F, Steinharter J, Bouchard G, Curran CR, Pan W, Baca SC, Seo JH, Lee GM, Michaelson MD, Chang SL, Waikar SS, Sonpavde G, Irizarry RA, Pomerantz M, De Carvalho DD, Choueiri TK, Freedman ML. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat Med. 2020 07; 26(7):1041-1043. PMID: 32572266.
    Citations: 1     Fields:    Translation:HumansCells
  6. Ambavane A, Yang S, Atkins MB, Rao S, Shah A, Regan MM, McDermott DF, Michaelson MD. Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma. Immunotherapy. 2020 01; 12(1):37-51. PMID: 31992108.
    Citations: 1     Fields:    
  7. Michaelson MD, Bellmunt J, Hudes GR, Goel S, Lee RJ, Kantoff PW, Stein CA, Lardelli P, Pardos I, Kahatt C, Nieto A, Cullell-Young M, Lewis NL, Smith MR. Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2012 May; 23(5):1234-1240. PMID: 32018582.
    Citations:    
  8. Motzer RJ, Jonasch E, Michaelson MD, Nandagopal L, Gore JL, George S, Alva A, Haas N, Harrison MR, Plimack ER, Sosman J, Agarwal N, Bhayani S, Choueiri TK, Costello BA, Derweesh IH, Gallagher TH, Hancock SL, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Lewis B, Manley B, McCreery B, McDonald A, Mortazavi A, Pierorazio PM, Ponsky L, Redman BG, Somer B, Wile G, Dwyer MA, Hammond LJ, Zuccarino-Catania G. NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. J Natl Compr Canc Netw. 2019 11 01; 17(11):1278-1285. PMID: 31693980.
    Citations: 9     Fields:    
  9. Deniz B, Ambavane A, Yang S, Altincatal A, Doan J, Rao S, Michaelson MD. Treatment sequences for advanced renal cell carcinoma: A health economic assessment. PLoS One. 2019; 14(8):e0215761. PMID: 31465470.
    Citations: 2     Fields:    Translation:Humans
  10. George DJ, Hessel C, Halabi S, Michaelson MD, Hahn O, Walsh M, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, Morris MJ, Choueiri TK. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. Oncologist. 2019 11; 24(11):1497-1501. PMID: 31399500.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  11. Michaelson MD, Gupta S, Agarwal N, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U, Larkin J, Rosbrook B, Wang E, Murphy D, Wang P, Lechuga MJ, Valota O, Shepard DR. A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors. Oncologist. 2019 09; 24(9):1151-e817. PMID: 31171735.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  12. Gao X, McDermott DF, Michaelson MD. Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma? Oncologist. 2019 06; 24(6):725-727. PMID: 31036769.
    Citations: 1     Fields:    Translation:Humans
  13. Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May; 15(15):1683-1695. PMID: 30968729.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  14. Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ. Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125]. Eur J Cancer. 2018 11; 103:287. PMID: 30270112.
    Citations: 1     Fields:    
  15. Choueiri TK, Michaelson MD, Posadas EM, Sonpavde GP, McDermott DF, Nixon AB, Liu Y, Yuan Z, Seon BK, Walsh M, Jivani MA, Adams BJ, Theuer CP. An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. Oncologist. 2019 02; 24(2):202-210. PMID: 30190302.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  16. Deniz B, Altincatal A, Ambavane A, Rao S, Doan J, Malcolm B, Michaelson MD, Yang S. Application of dynamic modeling for survival estimation in advanced renal cell carcinoma. PLoS One. 2018; 13(8):e0203406. PMID: 30161244.
    Citations:    Fields:    Translation:Humans
  17. McKay RR, Bossé D, Gray KP, Michaelson MD, Krajewski K, Jacene HA, Walsh M, Bellmunt J, Pomerantz M, Harshman LC, Choueiri TK. Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. Clin Cancer Res. 2018 09 01; 24(17):4081-4088. PMID: 29848570.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  18. Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018 05; 94:115-125. PMID: 29550566.
    Citations: 30     Fields:    Translation:HumansCTClinical Trials
  19. Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, Steinharter JA, Krajewski KM, Gao X, Schutz FA, McGregor B, Bossé D, Lalani AA, De Velasco G, Michaelson MD, McDermott DF, Choueiri TK. Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. Cancer Immunol Res. 2018 04; 6(4):402-408. PMID: 29437040.
    Citations: 8     Fields:    Translation:Humans
  20. Tannir NM, Figlin RA, Gore ME, Michaelson MD, Motzer RJ, Porta C, Rini BI, Hoang C, Lin X, Escudier B. Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. Clin Genitourin Cancer. 2017 Jun 20. PMID: 28711490.
    Citations: 6     Fields:    
  21. Rini BI, Gruenwald V, Jonasch E, Fishman MN, Tomita Y, Michaelson MD, Tarazi J, Cisar L, Hariharan S, Bair AH, Rosbrook B, Hutson TE. Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma. Target Oncol. 2017 06; 12(3):333-340. PMID: 28361451.
    Citations: 3     Fields:    Translation:Humans
  22. Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 06; 15(6):804-834. PMID: 28596261.
    Citations: 89     Fields:    Translation:Humans
  23. Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, Michaelson MD, Lee RJ, Saylor PJ, Wszolek MF, Feldman AS, Dahl DM, Zietman AL, Efstathiou JA. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017 06; 71(6):952-960. PMID: 28081860.
    Citations: 25     Fields:    Translation:Humans
  24. Michaelson MD, Hu C, Pham HT, Dahl DM, Lee-Wu C, Swanson GP, Vuky J, Lee RJ, Souhami L, Chang B, George A, Sandler H, Shipley W. A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524). Int J Radiat Oncol Biol Phys. 2017 04 01; 97(5):995-1001. PMID: 28333021.
    Citations: 8     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  25. Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, Dakhil S, George DJ, Morris MJ. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017 02 20; 35(6):591-597. PMID: 28199818.
    Citations: 103     Fields:    Translation:HumansCTClinical Trials
  26. Sella A, Michaelson MD, Matczak E, Simantov R, Lin X, Figlin RA. Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib. Clin Genitourin Cancer. 2017 04; 15(2):291-299.e1. PMID: 27638198.
    Citations: 5     Fields:    Translation:Humans
  27. Mahoney KM, Jacobus S, Bhatt RS, Song J, Carvo I, Cheng SC, Simpson M, Fay AP, Puzanov I, Michaelson MD, Atkins MB, McDermott DF, Signoretti S, Choueiri TK. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2016 08; 14(4):304-313.e6. PMID: 27036973.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  28. Selvi F, Faquin WC, Michaelson MD, August M. Three Synchronous Atypical Metastases of Clear Cell Renal Carcinoma to the Maxillary Gingiva, Scalp and the Distal Phalanx of the Fifth Digit: A Case Report. J Oral Maxillofac Surg. 2016 Jun; 74(6):1286.e1-9. PMID: 26954558.
    Citations: 3     Fields:    Translation:Humans
  29. Kwiatkowski DJ, Choueiri TK, Fay AP, Rini BI, Thorner AR, de Velasco G, Tyburczy ME, Hamieh L, Albiges L, Agarwal N, Ho TH, Song J, Pignon JC, Barrios PM, Michaelson MD, Van Allen E, Krajewski KM, Porta C, Pal S, Bellmunt J, McDermott DF, Heng DYC, Gray KP, Signoretti S. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 05 15; 22(10):2445-2452. PMID: 26831717.
    Citations: 46     Fields:    Translation:HumansCells
  30. Donskov F, Michaelson MD, Puzanov I, Davis MP, Bjarnason GA, Motzer RJ, Goldstein D, Lin X, Cohen DP, Wiltshire R, Rini BI. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. Br J Cancer. 2015 Dec 01; 113(11):1571-80. PMID: 26492223.
    Citations: 20     Fields:    Translation:Humans
  31. Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, Melichar B, Tomasek J, Kremer A, Kim HJ, Wood K, Dutcus C, Larkin J. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015 Nov; 16(15):1473-1482. PMID: 26482279.
    Citations: 152     Fields:    Translation:HumansCTClinical Trials
  32. Atkins MB, Gravis G, Drosik K, Demkow T, Tomczak P, Wong SS, Michaelson MD, Choueiri TK, Wu B, Navale L, Warner D, Ravaud A. Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study. J Clin Oncol. 2015 Oct 20; 33(30):3431-8. PMID: 26304872.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  33. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. 2015 Oct 01; 121(19):3435-43. PMID: 26058385.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  34. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Testicular Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Jun; 13(6):772-99. PMID: 26085393.
    Citations: 19     Fields:    Translation:Humans
  35. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Kidney cancer, version 3.2015. J Natl Compr Canc Netw. 2015 Feb; 13(2):151-9. PMID: 25691606.
    Citations: 61     Fields:    Translation:Humans
  36. Sonpavde G, Pond GR, Armstrong AJ, Galsky MD, Leopold L, Wood BA, Wang SL, Paolini J, Chen I, Chow-Maneval E, Mooney DJ, Lechuga M, Smith MR, Michaelson MD. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. BJU Int. 2014 Dec; 114(6b):E25-E31. PMID: 24298897.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  37. Hussain M, Corn PG, Michaelson MD, Hammers HJ, Alumkal JJ, Ryan CJ, Bruce JY, Moran S, Lee SY, Lin HM, George DJ. Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen. Clin Cancer Res. 2014 Aug 15; 20(16):4218-27. PMID: 24965748.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  38. Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, Porfiri E, Zalewski P, Kannourakis G, Staehler M, Tarazi J, Rosbrook B, Cisar L, Hariharan S, Kim S, Rini BI. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer. 2014 Jun 10; 110(12):2821-8. PMID: 24823696.
    Citations: 33     Fields:    Translation:HumansCTClinical Trials
  39. Négrier S, Bushmakin AG, Cappelleri JC, Korytowsky B, Sandin R, Charbonneau C, Michaelson MD, Figlin RA, Motzer RJ. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma. Eur J Cancer. 2014 Jul; 50(10):1766-1771. PMID: 24768571.
    Citations: 4     Fields:    Translation:Humans
  40. Sonpavde G, Pond GR, Armstrong AJ, Clarke SJ, Vardy JL, Templeton AJ, Wang SL, Paolini J, Chen I, Chow-Maneval E, Lechuga M, Smith MR, Michaelson MD. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2014 Oct; 12(5):317-24. PMID: 24806399.
    Citations: 32     Fields:    Translation:HumansCellsCTClinical Trials
  41. Cella D, Davis MP, Négrier S, Figlin RA, Michaelson MD, Bushmakin AG, Cappelleri JC, Sandin R, Korytowsky B, Charbonneau C, Matczak E, Motzer RJ. Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma. Cancer. 2014 Jun 15; 120(12):1871-80. PMID: 24634003.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  42. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Sircar K, Somer B, Wang J, Wilder RB, Dwyer MA, Kumar R. Kidney cancer, version 2.2014. J Natl Compr Canc Netw. 2014 Feb; 12(2):175-82. PMID: 24586079.
    Citations: 16     Fields:    Translation:Humans
  43. Aizer AA, Paly JJ, Michaelson MD, Rao SK, Nguyen PL, Kaplan ID, Niemierko A, Olumi AF, Efstathiou JA. Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer. J Oncol Pract. 2014 Mar; 10(2):107-12. PMID: 24399853.
    Citations: 4     Fields:    Translation:Humans
  44. Xu R, Horick N, McGovern FJ, Dahl DM, Feldman AS, Blute ML, Olumi AF, Michaelson MD. Prognostic significance of indeterminate lung nodules in renal cell carcinoma. Urol Oncol. 2014 Apr; 32(3):355-61. PMID: 24397994.
    Citations: 3     Fields:    Translation:Humans
  45. Michaelson MD, Oudard S, Ou YC, Sengeløv L, Saad F, Houede N, Ostler P, Stenzl A, Daugaard G, Jones R, Laestadius F, Ullèn A, Bahl A, Castellano D, Gschwend J, Maurina T, Chow Maneval E, Wang SL, Lechuga MJ, Paolini J, Chen I. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol. 2014 Jan 10; 32(2):76-82. PMID: 24323035.
    Citations: 47     Fields:    Translation:HumansCTClinical Trials
  46. Harmon CS, DePrimo SE, Figlin RA, Hudes GR, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Williams JA, Eisen T, Motzer RJ. Circulating proteins as potential biomarkers of sunitinib and interferon-a efficacy in treatment-naïve patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol. 2014 Jan; 73(1):151-61. PMID: 24220935.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  47. Molina AM, Hutson TE, Larkin J, Gold AM, Wood K, Carter D, Motzer R, Michaelson MD. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother Pharmacol. 2014 Jan; 73(1):181-9. PMID: 24190702.
    Citations: 27     Fields:    Translation:HumansCTClinical Trials
  48. Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw. 2013 Nov; 11(11):1364-72. PMID: 24225970.
    Citations: 4     Fields:    Translation:Humans
  49. Michaelson MD, Stadler WM. Predictive markers in advanced renal cell carcinoma. Semin Oncol. 2013 Aug; 40(4):459-64. PMID: 23972709.
    Citations: 6     Fields:    Translation:Humans
  50. Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013 May; 14(6):552-62. PMID: 23598172.
    Citations: 173     Fields:    Translation:HumansCTClinical Trials
  51. Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res. 2013 Jun 01; 19(11):3088-94. PMID: 23553848.
    Citations: 39     Fields:    Translation:HumansCells
  52. Michaelson MD, Zhu AX, Ryan DP, McDermott DF, Shapiro GI, Tye L, Chen I, Stephenson P, Patyna S, Ruiz-Garcia A, Schwarzberg AB. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study. Br J Cancer. 2013 Apr 16; 108(7):1393-401. PMID: 23511559.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  53. Paly JJ, Zietman AL, Nguyen PL, Beard C, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Multidisciplinary care and management of very low-risk prostate cancer. J Clin Oncol. 2013 Feb 20; 31(6_suppl):55. PMID: 28137047.
    Citations:    
  54. Hutson TE, Larkin JM, Gold A, Andresen C, Wood K, Motzer RJ, Michaelson MD. A phase Ib clinical trial of the multitargeted kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). J Clin Oncol. 2013 Feb 20; 31(6_suppl):358. PMID: 28136825.
    Citations:    
  55. Horick N, McGovern FJ, Dahl DM, Feldman AS, Blute ML, Olumi AF, Michaelson MD. Prognostic significance of indeterminate lung nodules in renal cell carcinoma. J Clin Oncol. 2013 Feb 20; 31(6_suppl):377. PMID: 28136903.
    Citations:    
  56. Rini BI, de La Motte Rouge T, Harzstark AL, Michaelson MD, Liu G, Grünwald V, Ingrosso A, Tortorici MA, Bycott P, Kim S, Bloom J, Motzer RJ. Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. Clin Genitourin Cancer. 2013 Jun; 11(2):107-14. PMID: 23391371.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  57. Saylor PJ, Mahmood U, Kunawudhi A, Smith MR, Palmer EL, Michaelson MD. Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer. J Nucl Med. 2012 Nov; 53(11):1670-5. PMID: 22984218.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  58. Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Sep 01; 30(25):3071-6. PMID: 22851571.
    Citations: 35     Fields:    Translation:Humans
  59. Cho DC, Hutson TE, Samlowski W, Sportelli P, Somer B, Richards P, Sosman JA, Puzanov I, Michaelson MD, Flaherty KT, Figlin RA, Vogelzang NJ. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer. 2012 Dec 15; 118(24):6055-62. PMID: 22674198.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  60. Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Motzer RJ. Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-a. Br J Cancer. 2012 May 08; 106(10):1587-90. PMID: 22568998.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  61. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB. Testicular cancer. J Natl Compr Canc Netw. 2012 Apr; 10(4):502-35. PMID: 22491049.
    Citations: 22     Fields:    Translation:Humans
  62. Saylor PJ, Escudier B, Michaelson MD. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy. Clin Genitourin Cancer. 2012 Jun; 10(2):77-83. PMID: 22382009.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  63. Rini BI, Escudier BJ, Michaelson MD, Negrier S, Gore ME, Oudard S, Clark J, Tarazi JC, Rosbrook B, Kim S, Motzer RJ. Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy. J Clin Oncol. 2012 Feb 10; 30(5_suppl):354. PMID: 28143045.
    Citations:    
  64. Saylor PJ, Michaelson MD. Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer? Oncologist. 2012; 17(2):288-90. PMID: 22267850.
    Citations: 1     Fields:    Translation:Humans
  65. Cella D, Bushmakin AG, Cappelleri JC, Charbonneau C, Michaelson MD, Motzer RJ. Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma. Br J Cancer. 2012 Feb 14; 106(4):646-50. PMID: 22240794.
    Citations: 11     Fields:    Translation:Humans
  66. Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, Choueiri TK, Coates A, Gupta N, Pradhan R, Qian J, Chen J, Scappaticci FA, Ricker JL, Carlson DM, Michaelson MD. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer. 2011 Dec; 47(18):2706-14. PMID: 22078932.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  67. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011 Dec 03; 378(9807):1931-9. PMID: 22056247.
    Citations: 475     Fields:    Translation:HumansCTClinical Trials
  68. Michaelson MD, Bellmunt J, Hudes GR, Goel S, Lee RJ, Kantoff PW, Stein CA, Lardelli P, Pardos I, Kahatt C, Nieto A, Cullell-Young M, Lewis NL, Smith MR. Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2012 May; 23(5):1234-1240. PMID: 21930687.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  69. Michaelson MD. Combination of targeted agents in metastatic renal cell carcinoma: a path forward or a dead-end street? Cancer. 2012 Apr 01; 118(7):1744-6. PMID: 21898374.
    Citations: 4     Fields:    Translation:Humans
  70. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB. Kidney cancer. J Natl Compr Canc Netw. 2011 Sep 01; 9(9):960-77. PMID: 21917622.
    Citations: 31     Fields:    Translation:Humans
  71. Ou Y, Michaelson MD, Sengeløv L, Saad F, Houede N, Ostler PJ, Stenzl A, Daugaard G, Jones RJ, Laestadius F, Bahl A, Castellano DE, Gschwend J, Maurina T, Ye D, Chen I, Wang S, Maneval EC, Oudard S. Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2011 May 20; 29(15_suppl):4515. PMID: 28023456.
    Citations:    
  72. Posadas EM, Tannir NM, Wong Y, Ernstoff MS, Kollmannsberger CK, Qian J, Ansell PJ, McKeegan EM, McKee MD, Ricker JL, Carlson DM, Michaelson MD. Phase II trial of linifanib in patients (pts) with advanced renal cell carcinoma (RCC): Analysis of pts receiving extended therapy. J Clin Oncol. 2011 May 20; 29(15_suppl):2543. PMID: 28022318.
    Citations:    
  73. Puzanov I, Michaelson MD, Cohen DP, Li S, Burnett P, Desai J. Evaluation of hand-foot syndrome (HFS) as a potential biomarker of sunitinib (SU) efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST). J Clin Oncol. 2011 May 20; 29(15_suppl):e21113. PMID: 28022868.
    Citations:    
  74. Motzer RJ, de La Motte Rouge T, Harzstark AL, Michaelson MD, Liu G, Gruenwald V, Ingrosso A, Tortorici MA, Bycott PW, Kim S, Rini BI. Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial. J Clin Oncol. 2011 May 20; 29(15_suppl):4547. PMID: 28023395.
    Citations:    
  75. Harmon CS, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Williams JA, Motzer RJ. Circulating protein biomarkers of sunitinib (SU) and interferon-a (IFN-a) efficacy in treatment (Tx)-naive patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2011 May 20; 29(15_suppl):10525. PMID: 28021773.
    Citations:    
  76. Hudes GR, Carducci MA, Choueiri TK, Esper P, Jonasch E, Kumar R, Margolin KA, Michaelson MD, Motzer RJ, Pili R, Roethke S, Srinivas S. NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Canc Netw. 2011 Feb; 9 Suppl 1:S1-29. PMID: 21335444.
    Citations: 13     Fields:    Translation:Humans
  77. Zama IN, Hutson TE, Elson P, Cleary JM, Choueiri TK, Heng DY, Ramaiya N, Michaelson MD, Garcia JA, Knox JJ, Escudier B, Rini BI. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer. 2010 Dec 01; 116(23):5400-6. PMID: 21105118.
    Citations: 40     Fields:    Translation:Humans
  78. Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Motzer RJ. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2011 Feb; 22(2):295-300. PMID: 20657034.
    Citations: 58     Fields:    Translation:Humans
  79. Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol. 2010 Jun; 183(6):2200-5. PMID: 20399451.
    Citations: 18     Fields:    Translation:Humans
  80. Cella D, Michaelson MD, Bushmakin AG, Cappelleri JC, Charbonneau C, Kim ST, Li JZ, Motzer RJ. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. Br J Cancer. 2010 Feb 16; 102(4):658-64. PMID: 20104222.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  81. Faris JE, Michaelson MD. Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC. Nat Rev Clin Oncol. 2010 Jan; 7(1):7-8. PMID: 20029441.
    Citations: 5     Fields:    
  82. Saylor PJ, Michaelson MD. New treatments for renal cell carcinoma: targeted therapies. J Natl Compr Canc Netw. 2009 Jun; 7(6):645-56. PMID: 19555586.
    Citations: 8     Fields:    Translation:Humans
  83. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw. 2009 Jun; 7(6):618-30. PMID: 19555584.
    Citations: 67     Fields:    Translation:Humans
  84. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw. 2009 Jun; 7(6):672-93. PMID: 19555582.
    Citations: 33     Fields:    Translation:Humans
  85. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Aug 01; 27(22):3584-90. PMID: 19487381.
    Citations: 634     Fields:    Translation:HumansCTClinical Trials
  86. Cella D, Michaelson MD, Cappelleri JC, Bushmakin AG, Charbonneau C, Kim ST, Li JZ, Motzer RJ. Quality of life (QOL) with sunitinib versus interferon-alfa (IFN-a) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): Final results. J Clin Oncol. 2009 May 20; 27(15_suppl):6529. PMID: 27964035.
    Citations:    
  87. Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Motzer RJ. Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2009 May 20; 27(15_suppl):5042. PMID: 27962940.
    Citations:    
  88. Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, Spicer B, Gurski C, Kantoff PW, Smith MR. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol. 2009 May; 20(5):913-20. PMID: 19403935.
    Citations: 58     Fields:    Translation:HumansCTClinical Trials
  89. Cella D, Cappelleri JC, Bushmakin A, Charbonneau C, Li JZ, Kim ST, Chen I, Michaelson MD, Motzer RJ. Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa. J Oncol Pract. 2009 Mar; 5(2):66-70. PMID: 20856722.
    Citations: 11     Fields:    
  90. Motzer RJ, Bukowski RM, Figlin RA, Hutson TE, Michaelson MD, Kim ST, Baum CM, Kattan MW. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2008 Oct 01; 113(7):1552-8. PMID: 18720362.
    Citations: 53     Fields:    Translation:Humans
  91. de Bazelaire C, Alsop DC, George D, Pedrosa I, Wang Y, Michaelson MD, Rofsky NM. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res. 2008 Sep 01; 14(17):5548-54. PMID: 18765547.
    Citations: 41     Fields:    Translation:HumansCTClinical Trials
  92. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008 Aug 01; 26(22):3743-8. PMID: 18669461.
    Citations: 134     Fields:    Translation:HumansCTClinical Trials
  93. Michaelson MD, Iliopoulos O, McDermott DF, McGovern FJ, Harisinghani MG, Oliva E. Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma. N Engl J Med. 2008 May 29; 358(22):2389-96. PMID: 18509125.
    Citations: 1     Fields:    Translation:Humans
  94. Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR. Management of complications of prostate cancer treatment. CA Cancer J Clin. 2008 Jul-Aug; 58(4):196-213. PMID: 18502900.
    Citations: 39     Fields:    Translation:HumansPHPublic Health
  95. Michaelson MD, Schwarzberg A, Ryan DP, McDermott DF, Shapiro GI, Tye L, Chen I, Selaru P, Wang E, Zhu A. A phase I dose-finding study of sunitinib (SU) in combination with gemcitabine (G) in patients (pts) with advanced solid tumors. J Clin Oncol. 2008 May 20; 26(15_suppl):14522. PMID: 27950768.
    Citations:    
  96. Figlin RA, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Négrier S, Huang X, Kim ST, Chen I, Motzer RJ. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2008 May 20; 26(15_suppl):5024. PMID: 27948827.
    Citations:    
  97. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007 Nov; 8(11):975-84. PMID: 17959415.
    Citations: 129     Fields:    Translation:HumansCTClinical Trials
  98. Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Wilding G. Sunitinib efficacy against advanced renal cell carcinoma. J Urol. 2007 Nov; 178(5):1883-7. PMID: 17868732.
    Citations: 56     Fields:    Translation:HumansCTClinical Trials
  99. Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 2007 Jul 02; 5:32. PMID: 17605814.
    Citations: 112     Fields:    Translation:HumansCTClinical Trials
  100. Michaelson MD. ASCO 2006 highlights: targeted therapy for renal cell carcinoma. Cancer Treat Rev. 2007 Jun; 33(4):381-90. PMID: 17367939.
    Citations: 1     Fields:    Translation:Humans
  101. Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007 Mar 20; 25(9):1038-42. PMID: 17369566.
    Citations: 82     Fields:    Translation:Humans
  102. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 Jan 11; 356(2):115-24. PMID: 17215529.
    Citations: 1565     Fields:    Translation:HumansCTClinical Trials
  103. McDougal WS, Tolkoff-Rubin NE, Michaelson MD, Mueller PR, Braaten K. Case records of the Massachusetts General Hospital. Case 28-2006. A 59-year-old man with masses in both kidneys. N Engl J Med. 2006 Sep 14; 355(11):1161-7. PMID: 16971723.
    Citations:    Fields:    Translation:Humans
  104. Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer. 2006 Aug 01; 107(3):530-5. PMID: 16804927.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  105. Lin AM, Rosenberg JE, Weinberg VK, Kelly WK, Michaelson MD, Hussain M, Wilding G, Gross ME, Small EJ. Clinical outcome of taxane-resistant (TR) hormone refractory prostate cancer (HRPC) patients (pts) treated with subsequent chemotherapy (ixabepilone (Ix) or mitoxantrone/prednisone (MP). J Clin Oncol. 2006 Jun 20; 24(18_suppl):4558. PMID: 27951999.
    Citations:    
  106. Rini BI, George DJ, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Margolin K, Hutson TE, Baum CM. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2006 Jun 20; 24(18_suppl):4522. PMID: 27951805.
    Citations:    
  107. Michaelson MD, Lee H, Kaufman DS, Kantoff PW, Finkelstein J, Smith MR. Annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized placebo-controlled trial. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4515. PMID: 27951772.
    Citations:    
  108. Houk BE, Amantea M, Motzer RJ, Michaelson MD, Rini BI, George DJ, Redman BG, Hudes GR, Poland B, Bello CL. Pharmacokinetics (PK) and efficacy of sunitinib in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2006 Jun 20; 24(18_suppl):4531. PMID: 27952043.
    Citations:    
  109. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Kim ST, Baum CM, Figlin RA. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2006 Jun 20; 24(18_suppl):LBA3. PMID: 27952543.
    Citations:    
  110. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006 Jun 07; 295(21):2516-24. PMID: 16757724.
    Citations: 305     Fields:    Translation:HumansCTClinical Trials
  111. Campbell J, Rosenthal DI, Raskin KA, Hornicek FJ, Michaelson MD. Use of an arterial tourniquet to achieve complete radiofrequency ablation of a renal metastasis. J Vasc Interv Radiol. 2006 Jun; 17(6):1051-5. PMID: 16778241.
    Citations:    Fields:    Translation:Humans
  112. de Bazelaire C, Rofsky NM, Duhamel G, Zhang J, Michaelson MD, George D, Alsop DC. Combined T2* and T1 measurements for improved perfusion and permeability studies in high field using dynamic contrast enhancement. Eur Radiol. 2006 Sep; 16(9):2083-91. PMID: 16583215.
    Citations: 23     Fields:    Translation:HumansCTClinical Trials
  113. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jan 01; 24(1):16-24. PMID: 16330672.
    Citations: 354     Fields:    Translation:HumansCTClinical Trials
  114. Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol. 2005 Nov 10; 23(32):8219-24. PMID: 16278476.
    Citations: 30     Fields:    Translation:Humans
  115. Rini B, Rixe O, Bukowski R, Michaelson MD, Wilding G, Hudes G, Bolte O, Steinfeldt H, Reich SD, Motzer R. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J Clin Oncol. 2005 Jun; 23(16_suppl):4509. PMID: 27946522.
    Citations:    
  116. Motzer RJ, Rini BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, Bukowski RM, George DJ, Kim ST, Baum CM. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). J Clin Oncol. 2005 Jun; 23(16_suppl):4508. PMID: 27946523.
    Citations:    
  117. Rosenberg JE, Kelly WK, Michaelson MD, Wilding G, Hussain M, Gross M, Small EJ. A randomized phase II study of ixabepilone (Ix) or mitoxantrone and prednisone (MP) in patients with taxane (T)-resistant hormone refractory prostate cancer (HRPC). J Clin Oncol. 2005 Jun; 23(16_suppl):4566. PMID: 27946397.
    Citations:    
  118. Michaelson MD, Gilligan T, Oh W, Kantoff P, Taplin ME, Izquierdo MA, Flores L, Smith MR. Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC). J Clin Oncol. 2005 Jun; 23(16_suppl):4517. PMID: 27946533.
    Citations:    
  119. De Bazelaire C, Rofsky NM, Duhamel G, Michaelson MD, George D, Alsop DC. Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1). Acad Radiol. 2005 Mar; 12(3):347-57. PMID: 15766695.
    Citations: 29     Fields:    Translation:HumansCTClinical Trials
  120. Katz-Brull R, Rofsky NM, Morrin MM, Pedrosa I, George DJ, Michaelson MD, Marquis RP, Maril M, Noguera C, Lenkinski RE. Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy. Am J Physiol Renal Physiol. 2005 Apr; 288(4):F637-41. PMID: 15572523.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  121. Michaelson MD, Rosenthal DI, Smith MR. Long-term bisphosphonate treatment of bone metastases from renal cell carcinoma. J Clin Oncol. 2004 Oct 15; 22(20):4233-4. PMID: 15483039.
    Citations: 2     Fields:    Translation:Humans
  122. Motzer RJ, Rini BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Zhu J, Kim ST, Baum C. SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4500. PMID: 28016015.
    Citations:    
  123. Michaelson MD, Marujo RM, Smith MR. Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res. 2004 Apr 15; 10(8):2705-8. PMID: 15102674.
    Citations: 15     Fields:    Translation:HumansCells
  124. Michaelson MD, Shipley WU, Heney NM, Zietman AL, Kaufman DS. Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder. Br J Cancer. 2004 Feb 09; 90(3):578-81. PMID: 14760367.
    Citations: 2     Fields:    Translation:Humans
  125. Shipley WU, Kaufman DS, McDougal WS, Dahl D, Michaelson MD, and Zietman AL. Cancer of the Bladder, Ureter and Renal Pelvis. Cancer: Principles and Practice of Oncology, Devita VT, Hellman S, Rosenberg SA, Editors. 2004; in press.
  126. Michaelson MD, Smith MR, Talcott JA. Prostate cancer (metastatic). Clin Evid. 2003 Dec; (10):1012-22. PMID: 15555135.
    Citations:    Fields:    Translation:Humans
  127. Michaelson MD, Smith MR. The role of bisphosphonates in the management of metastatic prostate cancer. Curr Oncol Rep. 2003 May; 5(3):245-9. PMID: 12667423.
    Citations: 2     Fields:    Translation:Humans
  128. Michaelson MD, Kaufman DS, Oh WK. Transitional cell carcinoma of the upper uroepithelial tract. Clin Adv Hematol Oncol. 2003 Feb; 1(2):102-4; discussion 105. PMID: 16224387.
    Citations:    Fields:    Translation:Humans
  129. Michaelson MD, Marujo RM and Smith MR . Cross-sectional analysis of markers of osteoblast and osteoclast activity in men with advanced prostate cancer. Proceedings of ASCO. 2003; 22:1521.
  130. Michaelson MD and Smith MR. Genitourinary malignancies. Cancer Chemotherapy and Biological Response Modifiers, Annual 21, Giaccone G, Schilsky R, Sondel P, Editors. 2003; 543-560.
  131. Michaelson MD, Smith MR. Genitourinary malignancies. Cancer Chemother Biol Response Modif. 2003; 21:547-64. PMID: 15338763.
    Citations: 2     Fields:    Translation:Humans
  132. George D, Michaelson MD, Oh W, Rietsma D, Laurent D, Mietlowski W, Wang Y, Dugan M, Kaelin W and Kantoff P . Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma. Proceedings of ASCO. 2003; 22:1548.
  133. Michaelson MD, Ryan DP, Fuchs CS, Supko JG, Garcia-Carbonero R, Paul Eder J, Clark JW. A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors. Cancer. 2003 Jan 01; 97(1):148-54. PMID: 12491516.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  134. Michaelson MD, Talcott JA, Smith MR. Prostate cancer: metastatic. Clin Evid. 2002 Dec; (8):881-90. PMID: 12603918.
    Citations:    Fields:    Translation:Humans
  135. Michaelson MD and Smith MR. Genitourinary malignancies. Cancer Chemotherapy and Biological Response Modifiers Annual 20, Pinedo HM, Longo DL, Chabner BA, Editors. 2002; 471-492.
  136. Michaelson MD, Ryan DP, Fram R, Clark JW, Appleman L, Kirvan M, Rattner B, Jennings L, Van Dijk S Boyden J, Trang J, Bonate P, Supko JG and Eder JP. A phase I clinical trial of ILX651, a dolastatin-15 analog, administered as a 30-minute intravenous infusion every other day x 3 every 21 days in patients with advanced solid tumors. Proceedings of ASCO. 2002; 21:414.
  137. Michaelson MD, Smith MR. Genitourinary malignancies. Cancer Chemother Biol Response Modif. 2002; 20:471-91. PMID: 12703221.
    Citations:    Fields:    Translation:Humans
  138. Rosenbaum DM, Rosenbaum PS, Gupta A, Michaelson MD, Hall DH, Kessler JA. Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid. Vision Res. 1997 Dec; 37(24):3445-51. PMID: 9425521.
    Citations: 13     Fields:    Translation:Animals
  139. Weiser M, Frishman WH, Michaelson MD, Abdeen MA. The pharmacologic approach to the treatment of obesity. J Clin Pharmacol. 1997 Jun; 37(6):453-73. PMID: 9208352.
    Citations: 8     Fields:    Translation:Humans
  140. Frishman WH, Michaelson MD. Use of calcium antagonists in patients with ischemic heart disease and systemic hypertension. Am J Cardiol. 1997 May 22; 79(10A):33-8; discussion 47-8. PMID: 9186065.
    Citations: 1     Fields:    Translation:Humans
  141. Michaelson MD, Mehler MF, Xu H, Gross RE, Kessler JA. Interleukin-7 is trophic for embryonic neurons and is expressed in developing brain. Dev Biol. 1996 Oct 10; 179(1):251-63. PMID: 8873768.
    Citations: 17     Fields:    Translation:AnimalsCells
  142. Michaelson MD, Bieri PL, Mehler MF, Xu H, Arezzo JC, Pollard JW, Kessler JA. CSF-1 deficiency in mice results in abnormal brain development. Development. 1996 Sep; 122(9):2661-72. PMID: 8787741.
    Citations: 27     Fields:    Translation:AnimalsCells
  143. Michaelson MD, Bieri PL, Mehler MF, Xu H, Arezzo JC, Pollard JW and Kessler JA. CSF-1 is a neural growth factor required for normal brain development. Development. 1996; 122:2661-2672.
  144. Kessler JA, Apfel SC, Dormia C and Michaelson MD . Paracrine regulation of neurotrophin expression in the peripheral nervous system. 1995.
  145. Rosenbaum DM, Michaelson M, Batter DK, Doshi P, Kessler JA. Evidence for hypoxia-induced, programmed cell death of cultured neurons. Ann Neurol. 1994 Dec; 36(6):864-70. PMID: 7998772.
    Citations: 19     Fields:    Translation:AnimalsCells
  146. Rosenbaum DM, Michaelson MD, Mehler MF and Kessler JA . Interleukin-9 ameliorates neuronal death from hypoxia in culture. 1994.
  147. Michaelson MD, Bieri PL, Mehler MF, Xu H, Arezzo JC, Pollard JW and Kessler JA . CSF-1 and its receptor are expressed in developing brain and mutation of CSF-1 impairs brain development. Proceedings of the Society for Neuroscience. 1994.
  148. Kessler JA, Ludlam WH, Freidin MM, Hall DH, Michaelson MD, Spray DC, Dougherty M, Batter DK. Cytokine-induced programmed death of cultured sympathetic neurons. Neuron. 1993 Dec; 11(6):1123-32. PMID: 8274279.
    Citations: 9     Fields:    Translation:AnimalsCells
  149. Michaelson MD, Xu H, Mehler MF and Kessler JA . Interleukin-7 is a neuronal growth factor. 1993.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Michaelson's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (346)
Explore
_
Co-Authors (85)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.